• Colorectal cancer (CRC) is one of the most common and costly cancer in United States 1 . Almost 70% of CRC patients are diagnosed at age 65 years or older 2 .
• The number of elderly patients with colorectal cancer is expected to be growing as a result of the increase in the aging population.
• Previous studies showed that the treatment cost for colorectal cancer had increased tremendously over the last 10 years 3, 4, 5, 6 .
• Timely information on dosing patterns and corresponding treatment costs is important to payers and health care providers.
Background
• To understand the CRC patient population using the claims database and estimate the cost difference of chemotherapy treatments within the elderly CRC patients. Each condition is assigned with a score of 1,2,3 or 6 depending on the risk of dying associated with this condition. The sum of the score can be tallied to yield the total comorbidity score. 9
• Overall cost: Total amount of payment made from the Medicare trust fund for the service covered by the claim in 2008
• Direct regimen cost: Revenue center payment amount recorded in the 2008 Medicare data
STATISTICAL ANALYSIS
• Univariate descriptive statistics were generated for the CRC cohorts
• Statistical comparisons between the groups using:
Methods & Materials
• Orally administered drugs in the CRC population are not captured by the Medicare Institutional data
• Stages of colorectal cancer were not clearly distinguished within the Medicare Institutional data
• Physician office data were not included in the analysis
Limitations
• Most CRC cancer patients (2,761 patients) use the drug combination of 5-FU, Leucovorin and Oxaliplatin (FOLFOX), the second commonly seen combination is 5-FU, Leucovorin, Oxaliplatin and Bevacizumab (1,450 patients), a small portion of the patients (458 patients) use 5-FU with Oxaliplatin only.
• The combination of 5-FU, Leucovorin and Oxaliplatin is the least expensive treatment ($17,685/patient).
• 5-FU and Oxaliplatin are administered at a slightly lower dose than used in combination with Leucovorin or Bevacizumab. 
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• Oxaliplatin has a higher mean dose per administration (186mg) when used with 5-FU only.
• Number of administrations for 5-FU and Oxaliplatin combination is slightly lower than the other two combinations.
• Around 60% of the patients received FOLFOX regimen as an adjuvant therapy after surgery.
• Regimens with Bevacizumab are mostly seen as a primary therapy for CRC patients.
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